Pharmacokinetics and Safety of Remdesivir in Pregnant and Non-Pregnant Women with COVID-19: Results from IMPAACT 2032.

Kristina M Brooks Kristin BaltrusaitisDiana F ClarkeSharon NachmanJennifer JaoMurli U PurswaniAllison AgwuChristy BeneriJaime G DevilleKathleen M PowisAlice M StekAhizechukwu C EkeDavid E ShapiroEdmund CapparelliElizabeth GreeneKathleen GeorgeDwight E YinPatrick Jean-PhilippeNahida ChakhtouraFrederic BoneKira BaconBenjamin JohnstonChristina RedingKathryn KerseyRita HumeniukBrookie M BestMark MirochnickJeremiah D Momper

Published in: The Journal of infectious diseases (2024)

Plasma remdesivir PK parameters were comparable between pregnant and non-pregnant women, and no safety concerns were identified based on our limited data. These findings suggest no dose adjustments are indicated for intravenous remdesivir during pregnancy.

Keyphrases

pregnant women
coronavirus disease
sars cov
pregnancy outcomes
electronic health record
big data
machine learning
low dose
respiratory syndrome coronavirus